-
Recent Posts
- Stroke Drug Boosts Stem Cell Therapy For Spinal Cord Injury In Rats
- An integrated in silico pipeline identifies a novel TF combination that promotes enhanced CST growth following injury
- Spike timing-dependent plasticity in the adult rat with chronic cervical spinal cord contusion
- Effect of PTEN antagonist peptide on the functional motor recovery in rat
- GDF10 promotes axonal regeneration and functional recovery: A novel gene therapy strategy for spinal cord injury
- GTX Medical and NeuroRecovery Technologies to merge
- Candidate Therapy From Quebec for Chronic SCI Being Developed in Parallel by Academics and Companies in Switzerland and the Netherlands
- Moving beyond the glial scar for spinal cord repair
- The Struggle to Make CNS Axons Regenerate: Why Has It Been so Difficult?
- The potential of electric field for promoting neurite guidance in spinal cord injury regeneration strategies
- Extraction and selective activation of muscle synergies through spinal stimulation for SCI
- Early limb unloading elicits long-term motor deficits involving motorneuron hyperexcitability associated with persistent alterations in glutamatergic synaptic plasticity in spinal cord injury
- The effects of a pro-angiogenic, RGD-functionalized, nanofiber composite biomaterial on mesenchymal stem cell-mediated repair of the injured spinal cord
- From wheelchair to walking after spinal cord injury
- ReNetX Bio, Inc. Announces U.S. FDA Authorization to Proceed for IND Application to Treat Patients with Chronic Spinal Cord Injury
Follow on Twitter
My TweetsSpinal Cord Injury Research and Science at Facebook
Categories
Archives
Tag Archives: Lisa McKerracher
BioAxone receives fast track grant for Rho Kinase 2 inhibitor to improve outcomes in chronic SCI
CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone BioSciences, Inc. announced today the receipt of a Fast-Track grant (R44 NS110290-01) from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, as part of the agency’s Small Business Innovation … Continue reading
UC Davis surgeons enroll the first patient in an acute spinal cord injury study
This compound was previously known as Cethrin. Dr Lisa McKerracher is Founder of BioAxone and inventor of Cethrin. It is being developed by Vertex Pharmaceuticals. UC Davis Health System – Sacramento, California – Neurosurgeons at UC Davis Health System have … Continue reading
Posted in spinal cord injury research
Tagged Cethrin, Lisa McKerracher, Vertex Pharmaceuticals, VX-210
2 Comments
